Meeting
2024 ASCO Gastrointestinal Cancers Symposium
Correlation of cancer testis antigen expression with high type-I interferon signal and prognosis in small bowel neuroendocrine tumors.
Authors
Reed I. Ayabe
The University of Texas MD Anderson Cancer Center, Houston, TX
Reed I. Ayabe , Yongwoo David Seo , Brenda Melendez , Rossana Lazcano Segura , Brittany C. Fields , Khalida M. Wani , Sarah Johnson , Russell Witt , Manoj Chelvanambi , Courtney Hudgens , Sharia D. Hernandez , Nadim J. Ajami , Jennifer Ann Wargo , Alexander J. Lazar , Daniel M. Halperin , Jeannelyn Estrella , Jess Maxwell
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer
Sub Track
Translational Research
Citation
J Clin Oncol 42, 2024 (suppl 3; abstr 596)
DOI
10.1200/JCO.2024.42.3_suppl.596
Abstract #
596
Poster Bd #
H7
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Genitourinary Cancers Symposium
AIM high: Epigenetic modulation and immune stimulation in bladder cancer.
First Author: Elizabeth Leone Koehne
Poster
2023 ASCO Annual Meeting
Spatially resolved multi-region transcriptomic subtyping and assessment of gene expression profiles associated with long-term benefit from chemo-immunotherapy in patients with extensive-stage small cell lung cancer (ES-SCLC).
First Author: Melina Peressini
Poster
2023 ASCO Annual Meeting
The genomic, transcriptomic, and immunological landscape of TROP2 in solid tumors.
First Author: Asaad Trabolsi
Poster
2019 ASCO Annual Meeting
ATALANTE-1 randomized phase III trial, OSE 2101 versus standard treatment as second- or third-line in HLA-A2 positive advanced non-small cell lung cancer (NSCLC) patients.
First Author: Enriqueta Felip